Interferon-Mediated Immunopathological Events Are Associated with Atypical Innate and Adaptive Immune Responses in Patients with Severe Acute Respiratory Syndrome

ABSTRACT It is not understood how immune inflammation influences the pathogenesis of severe acute respiratory syndrome (SARS). One area of strong controversy is the role of interferon (IFN) responses in the natural history of SARS. The fact that the majority of SARS patients recover after relatively moderate illness suggests that the prevailing notion of deficient type I IFN-mediated immunity, with hypercytokinemia driving a poor clinical course, is oversimplified. We used proteomic and genomic technology to systematically analyze host innate and adaptive immune responses of 40 clinically well-described patients with SARS during discrete phases of illness from the onset of symptoms to discharge or a fatal outcome. A novel signature of high IFN-α, IFN-γ, and IFN-stimulated chemokine levels, plus robust antiviral IFN-stimulated gene (ISG) expression, accompanied early SARS sequelae. As acute illness progressed, SARS patients entered a crisis phase linked to oxygen saturation profiles. The majority of SARS patients resolved IFN responses at crisis and expressed adaptive immune genes. In contrast, patients with poor outcomes showed deviated ISG and immunoglobulin gene expression levels, persistent chemokine levels, and deficient anti-SARS spike antibody production. We contend that unregulated IFN responses during acute-phase SARS may culminate in a malfunction of the switch from innate immunity to adaptive immunity. The potential for the use of the gene signatures we describe in this study to better assess the immunopathology and clinical management of severe viral infections, such as SARS and avian influenza (H5N1), is therefore worth careful examination.

[1]  Ding-Mei Zhang,et al.  Pathogenesis of severe acute respiratory syndrome. , 2008, Chinese medical journal.

[2]  S. Akira,et al.  Control of coronavirus infection through plasmacytoid dendritic-cell–derived type I interferon , 2007, Blood.

[3]  Yan Li,et al.  Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus , 2007, Nature.

[4]  Tao Han,et al.  Improvement in the Reproducibility and Accuracy of DNA Microarray Quantification by Optimizing Hybridization Conditions , 2006, BMC Bioinformatics.

[5]  Yi Guan,et al.  Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia , 2006, Nature Medicine.

[6]  Hanlee P. Ji,et al.  The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. , 2006, Nature biotechnology.

[7]  Paul Garner,et al.  SARS: Systematic Review of Treatment Effects , 2006, PLoS medicine.

[8]  B. Cowling,et al.  Clinical prognostic rules for severe acute respiratory syndrome in low- and high-resource settings. , 2006, Archives of internal medicine.

[9]  J. Habbema,et al.  Association of SARS susceptibility with single nucleic acid polymorphisms of OAS1 and MxA genes: a case-control study , 2006, BMC infectious diseases.

[10]  A. Takaoka,et al.  Interferon signalling network in innate defence , 2006, Cellular microbiology.

[11]  J. Chan,et al.  Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[12]  Arnab Gupta,et al.  Down‐regulation of locus‐specific human lymphocyte antigen class I expression in Epstein–Barr virus‐associated gastric cancer , 2006, Cancer.

[13]  K. To,et al.  How the SARS coronavirus causes disease: host or organism? , 2005, The Journal of pathology.

[14]  X. Wang,et al.  Effect of Hepatitis C Virus Core Protein on the Molecular Profiling of Human B Lymphocytes , 2006, Molecular medicine.

[15]  Maqc Consortium The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements , 2006, Nature Biotechnology.

[16]  E. Fish,et al.  Stats: multifaceted regulators of transcription. , 2005, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[17]  J. Sung,et al.  Early Enhanced Expression of Interferon-Inducible Protein-10 (CXCL-10) and Other Chemokines Predicts Adverse Outcome in Severe Acute Respiratory Syndrome , 2005, Clinical chemistry.

[18]  P. Österlund,et al.  Severe Acute Respiratory Syndrome Coronavirus Fails To Activate Cytokine-Mediated Innate Immune Responses in Cultured Human Monocyte-Derived Dendritic Cells , 2005, Journal of Virology.

[19]  Y. Lau,et al.  Chemokine up-regulation in SARS-coronavirus–infected, monocyte-derived human dendritic cells , 2005, Blood.

[20]  Tzu-Hao Wang,et al.  Molecular signature of clinical severity in recovering patients with severe acute respiratory syndrome coronavirus (SARS-CoV) , 2005, BMC Genomics.

[21]  Zheng-hong Yuan,et al.  Gene expression profiles in peripheral blood mononuclear cells of SARS patients. , 2005, World journal of gastroenterology.

[22]  C. Agrati,et al.  Coordinate induction of IFN-α and -γ by SARS-CoV also in the absence of virus replication , 2005, Virology.

[23]  Mark Chappell,et al.  A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury , 2005, Nature Medicine.

[24]  Y. Guan,et al.  Cytokine Responses in Severe Acute Respiratory Syndrome Coronavirus-Infected Macrophages In Vitro: Possible Relevance to Pathogenesis , 2005, Journal of Virology.

[25]  Giovanna Lombardi,et al.  Type I interferons and the innate immune response--more than just antiviral cytokines. , 2005, Molecular immunology.

[26]  T. Kirikae,et al.  Polymorphisms of interferon-inducible genes OAS-1 and MxA associated with SARS in the Vietnamese population , 2005, Biochemical and Biophysical Research Communications.

[27]  F. Lin,et al.  Representative appressorium stage cDNA library of Magnaporthe grisea. , 2005, Journal of Zhejiang University. Science. B.

[28]  K. Kain,et al.  Fatal Severe Acute Respiratory Syndrome Is Associated with Multiorgan Involvement by Coronavirus , 2005, The Journal of infectious diseases.

[29]  R. Perng,et al.  Clinical Features and Outcomes of Severe Acute Respiratory Syndrome and Predictive Factors for Acute Respiratory Distress Syndrome , 2005, Journal of the Chinese Medical Association.

[30]  M. Salto‐Tellez,et al.  ARDS in SARS: cytokine mediators and treatment implications , 2004, Cytokine.

[31]  S. Asa,et al.  Pulmonary pathology of severe acute respiratory syndrome in Toronto , 2005, Modern Pathology.

[32]  Renji Reghunathan,et al.  Expression profile of immune response genes in patients with Severe Acute Respiratory Syndrome , 2005, BMC Immunology.

[33]  H. Deng,et al.  Neutralizing Antibodies in Patients with Severe Acute Respiratory Syndrome-Associated Coronavirus Infection , 2004, The Journal of Infectious Diseases.

[34]  V. Wong,et al.  Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients , 2004, Journal of Clinical Virology.

[35]  L. Malmgaard Induction and regulation of IFNs during viral infections. , 2004, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[36]  Qingling Zhang,et al.  Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS‐CoV) in SARS patients: implications for pathogenesis and virus transmission pathways , 2004, The Journal of pathology.

[37]  G. Navis,et al.  Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis , 2004, The Journal of pathology.

[38]  J. Sung,et al.  Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome , 2004, Clinical and experimental immunology.

[39]  Z. Zou,et al.  Prognostic Factors for Severe Acute Respiratory Syndrome: A Clinical Analysis of 165 Cases , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  K. Schroder,et al.  Interferon- : an overview of signals, mechanisms and functions , 2004 .

[41]  K. Schroder,et al.  Interferon-gamma: an overview of signals, mechanisms and functions. , 2004, Journal of leukocyte biology.

[42]  Xiaolei Yin,et al.  Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection. , 2004, The Journal of infectious diseases.

[43]  John L. Sullivan,et al.  Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus , 2003, Nature.

[44]  O. Tsang,et al.  Outcomes and Prognostic Factors in 267 Patients with Severe Acute Respiratory Syndrome in Hong Kong , 2003, Annals of Internal Medicine.

[45]  S. Lai,et al.  Severe Acute Respiratory Syndrome: Clinical Outcome and Prognostic Correlates , 2003, Emerging infectious diseases.

[46]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[47]  Arul Earnest,et al.  Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. , 2003, JAMA.

[48]  Arthur S Slutsky,et al.  Critically ill patients with severe acute respiratory syndrome. , 2003, JAMA.

[49]  Deepali Kumar,et al.  Severe Acute Respiratory Syndrome (SARS) in a Liver Transplant Recipient and Guidelines for Donor SARS Screening , 2003, American Journal of Transplantation.

[50]  M. Avendaño,et al.  Clinical course and management of SARS in health care workers in Toronto: a case series. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[51]  J. Sung,et al.  Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis , 2003, BMJ : British Medical Journal.

[52]  R. Strieter,et al.  Host innate defenses in the lung: the role of cytokines , 2003, Current opinion in infectious diseases.

[53]  L. Poon,et al.  Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia : a prospective study , 2003 .

[54]  Yi Guan,et al.  Lung pathology of fatal severe acute respiratory syndrome , 2003, The Lancet.

[55]  K. Jerome,et al.  APOPTOSIS PREVENTION AS A MECHANISM OF IMMUNE EVASION , 2003, International reviews of immunology.

[56]  R. Salomon,et al.  Critical Role for STAT4 Activation by Type 1 Interferons in the Interferon-γ Response to Viral Infection , 2002, Science.

[57]  E. Fish,et al.  Review: IFN-α/β Receptor Interactions to Biologic Outcomes: Understanding the Circuitry , 2002 .

[58]  L. Shao,et al.  Impaired Regulation of HLA-DR Expression in Human Immunodeficiency Virus-Infected Monocytes , 2002, Clinical and Vaccine Immunology.

[59]  E. Fish,et al.  Review: IFN-alpha/beta receptor interactions to biologic outcomes: understanding the circuitry. , 2002, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[60]  B. Williams,et al.  Functional classification of interferon‐stimulated genes identified using microarrays , 2001, Journal of leukocyte biology.